BUSINESS HIGHLIGHTS

FIRST-QUARTER 2024 RESULTS

TOTAL COMPANY

$10.0B

SALES WORLDWIDE

+10.8%

Organic* sales growth for underlying base business**

$0.98

ADJUSTED DILUTED EPS

KEY BUSINESS UNITS*

14.3%

MEDICAL DEVICES

5.4%

DIAGNOSTICS

13.7%

ESTABLISHED PHARMACEUTICALS

7.7%

NUTRITION

RAISING MIDPOINT FULL-YEAR GUIDANCE RANGES

$4.55 to $4.70

ADJUSTED DILUTED EPS

8.5% to 10%

Range for organic sales growth excluding COVID-19 testing-related sales

INNOVATION IN CONCUSSION ASSESSMENT

FDA clearance of i-STAT® TBI cartridge, which helps assess a person with a suspected traumatic brain injury (TBI).

NEWLY CLEARED TEST CAN BE PERFORMED
outside of traditional hospital settings, making it more accessible and convenient for patients.

FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE

FDA approval for TriClip™ transcatheter edge-to-edge repair (TEER) system.

SYSTEM IS SPECIFICALLY DESIGNED FOR THE TREATMENT OF TRICUSPID REGURGITATION (TR), OR A LEAKY TRICUSPID VALVE.

SUPPORTING ADULTS ON WEIGHT-LOSS JOURNEYS

LAUNCHED THE NEW PROTALITY™ BRAND, INCLUDING A HIGH-PROTEIN NUTRITION SHAKE.

CREATED TO PROVIDE NUTRITIONAL SUPPORT AND HELP PRESERVE MUSCLE FOR THE GROWING NUMBER OF ADULTS PURSUING WEIGHT LOSS.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


**Excludes the impact of COVID-19 testing sales.

1 On a GAAP basis, first-quarter 2024 Abbott sales increased 2.2%.

2 First-quarter 2024 GAAP diluted EPS was $0.70.

3 Excludes the impact of COVID-19 testing sales.

4 Adjusted diluted EPS includes specified items.

5 Specified items are related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.55 to $4.70 for the full-year 2024.

6 Abbott has not provided the related GAAP financial measure for organic sales growth excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported organic sales growth. In addition, as the COVID-19 pandemic has subsided to an endemic state, the company has determined that it is unable to predict such measurable certainty.